MX2019007606A - Derivados de triazintriona y su uso como moduladores de receptor de neurotrofinas y receptor de tirosina quinasa. - Google Patents
Derivados de triazintriona y su uso como moduladores de receptor de neurotrofinas y receptor de tirosina quinasa.Info
- Publication number
- MX2019007606A MX2019007606A MX2019007606A MX2019007606A MX2019007606A MX 2019007606 A MX2019007606 A MX 2019007606A MX 2019007606 A MX2019007606 A MX 2019007606A MX 2019007606 A MX2019007606 A MX 2019007606A MX 2019007606 A MX2019007606 A MX 2019007606A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- sup
- modulators
- tyrosine kinases
- neurotrophin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651706 | 2016-12-21 | ||
| PCT/GB2017/053868 WO2018115891A1 (en) | 2016-12-21 | 2017-12-21 | Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007606A true MX2019007606A (es) | 2020-07-29 |
Family
ID=60923799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007606A MX2019007606A (es) | 2016-12-21 | 2017-12-21 | Derivados de triazintriona y su uso como moduladores de receptor de neurotrofinas y receptor de tirosina quinasa. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200113910A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3558320A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020502225A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190098982A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110167558A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017380583A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019012709A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3046289A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL267086A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019007606A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019120431A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018115891A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11352332B2 (en) | 2018-02-26 | 2022-06-07 | AlzeCure Pharma AB | Triazine derivatives for treating diseases relating to neurotrophins |
| GB201810668D0 (en) | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
| GB201912404D0 (en) * | 2019-08-29 | 2019-10-16 | AlzeCure Pharma AB | New compounds |
| CN113057957A (zh) * | 2021-03-30 | 2021-07-02 | 福建中医药大学 | 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途 |
| CN113893334A (zh) * | 2021-10-19 | 2022-01-07 | 内蒙古医科大学第二附属医院 | 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2718799A1 (de) * | 1977-04-27 | 1978-11-09 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer |
| CA2765030C (en) * | 2009-06-09 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| WO2011070177A2 (en) * | 2009-12-11 | 2011-06-16 | Baltic Technology Development, Ltd. | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
-
2017
- 2017-12-21 EP EP17825283.9A patent/EP3558320A1/en not_active Withdrawn
- 2017-12-21 BR BR112019012709A patent/BR112019012709A2/pt not_active Application Discontinuation
- 2017-12-21 AU AU2017380583A patent/AU2017380583A1/en not_active Abandoned
- 2017-12-21 MX MX2019007606A patent/MX2019007606A/es unknown
- 2017-12-21 CA CA3046289A patent/CA3046289A1/en not_active Abandoned
- 2017-12-21 CN CN201780078675.XA patent/CN110167558A/zh active Pending
- 2017-12-21 KR KR1020197018642A patent/KR20190098982A/ko not_active Ceased
- 2017-12-21 RU RU2019120431A patent/RU2019120431A/ru not_active Application Discontinuation
- 2017-12-21 JP JP2019534090A patent/JP2020502225A/ja active Pending
- 2017-12-21 US US16/471,923 patent/US20200113910A1/en not_active Abandoned
- 2017-12-21 WO PCT/GB2017/053868 patent/WO2018115891A1/en not_active Ceased
-
2019
- 2019-06-04 IL IL267086A patent/IL267086A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018115891A1 (en) | 2018-06-28 |
| RU2019120431A (ru) | 2021-01-22 |
| IL267086A (en) | 2019-08-29 |
| RU2019120431A3 (cg-RX-API-DMAC7.html) | 2021-03-09 |
| AU2017380583A1 (en) | 2019-06-27 |
| US20200113910A1 (en) | 2020-04-16 |
| CA3046289A1 (en) | 2018-06-28 |
| CN110167558A (zh) | 2019-08-23 |
| BR112019012709A2 (pt) | 2019-11-26 |
| JP2020502225A (ja) | 2020-01-23 |
| EP3558320A1 (en) | 2019-10-30 |
| KR20190098982A (ko) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202108745B (en) | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| MY159327A (en) | Jak kinase modulating quinazoline derivatives and methods of use thereof | |
| MX2014006027A (es) | Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
| PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX376465B (es) | Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret. | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| WO2021016112A3 (en) | Non-sedating dexmedetomidine treatment regimens | |
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| PH12015501326A1 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer | |
| PH12017500146B1 (en) | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof | |
| EA201291220A1 (ru) | Производные аминопиримидина в качестве модуляторов lrrk2 | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| TN2016000458A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer. | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| EA033281B1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| MX2025002953A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis | |
| MY206763A (en) | Piperidinyl-3-(aryloxy)propanamides and propanoates | |
| PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| BR112022009805A2 (pt) | Derivados de piridopirimidinona como antagonistas de ahr | |
| MX388786B (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
| WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| PH12016502432A1 (en) | 1h-1,8-naphthyridin-2-ones as anti proliferative compounds | |
| PH12017501736A1 (en) | Indole derivatives |